Pupil dilation evaluation of two mydriatic dosing profiles delivered by the Optejet.

To compare pupil dilation achieved by a single microdose versus two microdoses of tropicamide-phenylephrine fixed combination (TR-PH FC) delivered by the Optejet. In this assessor-masked, crossover, noninferiority study, 60 volunteers underwent two treatment visits and received either one (∼8 μl) or two sprays (∼16 μl) of TR-PH FC to both eyes in randomly assigned order. At 35 min postdose, mean change in pupil diameter was 4.

Twelve-month clinical outcomes after implantation of a new, modular, anterior shape-changing fluid optic intraocular lens.

Purpose: To report the initial safety and effectiveness profile for an anterior shape-changing, modular IOL, Juvene IOL (JIOL), for the treatment of aphakia and presbyopia after removal of the natural crystalline lens due to cataract.

Setting: 2 private practices in Monterrey and Tijuana, Mexico.

Design: Exploratory prospective multicenter open-label noncomparative clinical trial.

Eighty-micron flap femtosecond-assisted LASIK for the correction of myopia and myopic astigmatism.

Purpose: To evaluate the safety and efficacy of 80-μm flap femtosecond laser-assisted LASIK and the early clinical and refractive outcomes in the correction of myopia and myopic astigmatism.

Setting: Private practice, outpatient.

Design: Prospective study.

Corneal remodeling after implantation of a shape-changing inlay concurrent with myopic or hyperopic laser in situ keratomileusis.

Purpose: To compare the induced addition (add)-power profile and epithelial remodeling between patients receiving hyperopic and myopic laser in situ keratomileusis (LASIK) concurrently with implantation of a corneal shape-changing inlay.

Setting: Specialty clinics in Monterrey and Tijuana, Mexico.

Design: Retrospective case series.

Pharmacodynamic profile of mydriatic agents delivered by ocular piezo-ejection microdosing compared with conventional eyedropper.

Aim: Eyedroppers deliver medication volumes exceeding conjunctival absorptive capacity, causing spillage and risking ocular/systemic complications. We evaluated piezoelectric microdosing. Results/methodology: Subjects (n = 102) received precision microdroplet delivery of phenylephrine (2.

Structural Changes Induced by a Corneal Shape-Changing Inlay, Deduced From Optical Coherence Tomography and Wavefront Measurements.

Purpose: Changes to the anterior stroma and epithelium induced by a meniscus-shaped corneal inlay are presented. The hypothesis that local curvature is a driver of epithelial remodeling is tested.

Methods: Records of 30 subjects enrolled in a prospective clinical investigation of the inlay, implanted in emmetropic presbyopic subjects, were analyzed.

A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease.

Background: Dry eye disease (DED), a chronic disorder affecting the tear film and lacrimal functional unit, is a widely prevalent condition associated with significant burden and unmet treatment needs. Since specific neural circuits play an important role in maintaining ocular surface health, microelectrical stimulation of these pathways could present a promising new approach to treating DED. This study evaluated the efficacy and safety of nasal electrical stimulation in patients with DED.

Range of refractive independence and mechanism of action of a corneal shape-changing hydrogel inlay: results and theory.

Purpose: To demonstrate the independence of visual performance over a range of preoperative refraction and age in presbyopes implanted with a corneal shape-changing inlay (Raindrop Near Vision Inlay).

Setting: Two multispecialty clinics, Monterrey and Tijuana, Mexico.

Design: Prospective case series.

Safety and efficacy of a hydrogel inlay with laser in situ keratomileusis to improve vision in myopic presbyopic patients: one-year results.

Purpose: To study the safety and efficacy of implanting a hydrogel corneal inlay (Raindrop Near Vision Inlay) concurrently with performing laser in situ keratomileusis (LASIK) to treat myopic presbyopia and to compare the results with results of the same treatment in emmetropic and hyperopic patients.

Setting: Two private clinics, Tijuana and Monterrey, Mexico.

Design: Prospective nonrandomized clinical trial.

Unfolded protein response activation in cataracts.

Purpose: To analyze the expression of 78 kDa glucose-regulated protein (GRP78) and activating transcription factor 6 (ATF6), 2 factors in the unfolded protein response (UPR), in age-related and diabetes-associated cataract.

Setting: Universidad Autónoma de Aguascalientes, Aguascalientes, México.

Design: Experimental study.

Intraocular polyimide intraocular lens haptic breakage long-term postoperatively.

Unlabelled: We present 2 cases of 3-piece silicone intraoculanbsp;r lenses (IOLs) with broken polyimide haptics. In the first case, the IOL was implanted in the anterior chamber after posterior capsule rupture. Twelve years later, it was explanted and exchanged because of bullous keratopathy.

Combined hydrogel inlay and laser in situ keratomileusis to compensate for presbyopia in hyperopic patients: one-year safety and efficacy.

Purpose: To perform a feasibility study of the safety and efficacy of a corneal-contouring inlay with concurrent laser in situ keratomileusis (LASIK) to treat hyperopic presbyopia.

Setting: Private clinic, Tijuana, Mexico.

Design: Prospective interventional case series.

One-year safety and efficacy results of a hydrogel inlay to improve near vision in patients with emmetropic presbyopia.

Purpose: To conduct a feasibility study of the safety and efficacy of a corneal contouring inlay as a treatment for emmetropic presbyopia.

Methods: The Raindrop corneal inlay (ReVision Optics, Inc., Lake Forest, CA) was implanted on the corneal stromal bed beneath a keratotomy flap in 20 nondominant eyes of 20 patients.

Prospective, randomized, double-blind, contralateral eye comparison of myopic LASIK with optimized aspheric or prolate ablations.

Purpose: To compare the postoperative outcomes of aspheric or prolate LASIK for myopia and myopic astigmatism.

Methods: In this double-blind, bilateral, randomized trial, 40 patients (80 eyes) with -0.75 to -7.

Gabapentin for postoperative pain after photorefractive keratectomy: a prospective, randomized, double-blind, placebo-controlled trial.

Purpose: To determine whether treatment with oral gabapentin reduces postoperative pain after photorefractive keratectomy (PRK).

Methods: This prospective, randomized, double-blind, placebo-controlled study comprised 40 patients scheduled for bilateral PRK. Exclusion criteria were previous refractive surgery; diseases that could affect epithelial healing; use of antihistamines, nonsteroidal anti-inflammatory drugs, or steroids; and use of mitomycin C during PRK.

Correction of astigmatism after cataract surgery using the light adjustable lens: a 1-year follow-up pilot study.

Purpose: The management of preoperative and residual astigmatism is critical to obtain optimized uncorrected visual acuity. The aim of this study was to determine whether residual astigmatism could be precisely corrected postoperatively using the Light Adjustable Lens (LAL, Calhoun Vision Inc) and to determine the stability of the adjusted refraction.

Methods: Ten eyes of 10 patients with cataract and corneal astigmatism between 1.

Corneal endothelial safety after ultraviolet light treatment of the light-adjustable intraocular lens.

Purpose: To assess the safety to the corneal endothelium of ultraviolet (UV) light treatment to a light-adjustable intraocular lens (IOL).

Setting: Codet Vision Institute, Tijuana, Mexico.

Design: Cohort study.

Use of the light-adjustable lens to correct astigmatism after cataract surgery.

Aim: To determine if residual cylindrical refractive error after cataract surgery can be adjusted using the light-adjustable lens (LAL).

Methods: The LAL is a photosensitive silicone intraocular lens whose power can be adjusted post-operatively using UV light at 365 nm. A digital light delivery device (DLD) is used to adjust LAL power in situ to correct residual refractive errors non-invasively.

Correction of myopia after cataract surgery with a light-adjustable lens.

Purpose: To determine whether residual myopia could be corrected postoperatively using the light-adjustable lens (LAL) technology in patients undergoing cataract surgery and LAL implantation.

Design: A prospective clinical study was conducted at Codet Vision Institute in Tijuana, Mexico. The LALs were implanted that would purposely result in myopic errors of up to -1.

Correction of residual hyperopia after cataract surgery using the light adjustable intraocular lens technology.

Purpose: To determine whether residual hyperopia could be corrected postoperatively using the light adjustable lens technology in patients undergoing cataract surgery and light adjustable lens implantation.

Design: Prospective, nonrandomized clinical trial.

Methods: Fourteen eyes of 14 patients were studied.

Topographically guided laser in situ keratomileusis for myopia using a customized aspherical treatment zone.

Purpose: To assess the efficacy, predictability, safety, and quality-of-life effects of topography-guided laser in situ keratomileusis (LASIK) for the correction of myopia with astigmatism using the EC-5000 CXII excimer laser equipped with a customized aspheric treatment zone algorithm.

Setting: Ophthalmology clinics in the United States and Mexico.

Methods: In a multicenter United States Food and Drug Administration study of topography-guided LASIK, 4 centers enrolled 135 eyes with a spherical manifest refraction error ranging from -0.